Market Overview

The Global Ulcerative Colitis Market was valued at USD 6,998.5 million in 2023 and is expected to reach USD 11,582.6 million by 2031 while growing at a CAGR of 6.5% during the forecast period (2024-2031).

*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Market Dynamics

This section of the report will analyze various driving and restraining factors that are expected to have a significant impact on the global ulcerative colitis market growth. Ulcerative colitis, an inflammatory bowel disease (IBD), leads to inflammation and ulcers (sores) within the digestive tract. This condition primarily affects the innermost lining of the large intestine, known as the colon, as well as the rectum. Symptoms typically develop gradually over time rather than abruptly in most individuals.

Continual progress in treatment modalities, encompassing biologic therapies, immunomodulators, and targeted therapies, coupled with the increasing prevalence of ulcerative colitis and heightened awareness and diagnosis, propels market expansion. However, the market's growth is impeded by high treatment costs and adverse treatment effects.

Furthermore, the global ulcerative colitis industry will be analyzed through various tools including PESTLE analysis, and Porter’s analysis.

Segmentation – By Disease Type Analysis

The Global Ulcerative Colitis Market is segmented among Mild UC, Moderate UC, and Severe UC, based on Disease Type. In 2023, Mild UC accounted for the majority of the market share*.

*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Segmentation – By Molecule Type Analysis

The Global Ulcerative Colitis Market is segmented among Biologics, and Small Molecules, based on Molecule Type. In 2023, Small Molecules accounted for the majority of the market share*.

*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Global Ulcerative Colitis Market: Regional Analysis

Based on region, the market is divided into six regions including North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. In 2023, North America dominated the market with the highest market share, while Asia Pacific is expected to grow with the highest CAGR during the forecast period (2024 – 2031).

*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Competitive Landscape

Some of the key players operating in the market are Ajinomoto Co. Inc, AstraZeneca Plc, Abbott Laboratories, Eli-Lily, Merck, Index Pharmaceuticals Holdings AB, GlaxoSmithKline Plc, Pfizer Inc, Sanofi SA, and Johnson & Johnson.

Table of Contents:

1. Research Methodology and Market Scope

• Research Methodology

• Market Scope

2. Executive Summary

3. Global Ulcerative Colitis Market Dynamics

• Drivers

• Restraints

• Opportunity

4. Global Ulcerative Colitis Industry Analysis

• PEST Analysis

• Porter's Five Force Analysis

• Recent Deals Analysis

5. Global Ulcerative Colitis Market Segmentation, By Disease Type

• Global Ulcerative Colitis Market Share Analysis, By Disease Type

• Global Ulcerative Colitis Market Growth Analysis, By Disease Type

• Global Ulcerative Colitis Market Trends, By Disease Type

o Mild UC

o Moderate UC

o Severe UC

6. Global Ulcerative Colitis Market Segmentation, By Molecule Type

• Global Ulcerative Colitis Market Share Analysis, By Molecule Type

• Global Ulcerative Colitis Market Growth Analysis, By Molecule Type

• Global Ulcerative Colitis Market Trends, By Molecule Type

o Biologics

o Small Molecules

7. Global Ulcerative Colitis Market Segmentation, By Route of Administration

• Global Ulcerative Colitis Market Share Analysis, By Route of Administration

• Global Ulcerative Colitis Market Growth Analysis, By Route of Administration

• Global Ulcerative Colitis Market Trends, By Route of Administration

o Oral

o Injectables

8. Global Ulcerative Colitis Market Segmentation, By Region

• Global Ulcerative Colitis Market Share Analysis, By Region

• Global Ulcerative Colitis Market Growth Analysis, By Region

• Global Ulcerative Colitis Market Trends, By Region

o North America

o Europe

o Asia Pacific

o Latin America

o Middle East

o Africa

9. Competitive Landscape

• Ajinomoto Co. Inc.*

o Company Overview

o Financial Performance

o Key Development/Strategies

o SWOT Analysis

• AstraZeneca Plc

• Abbott Laboratories

• Eli-Lily

• Merck

• Index Pharmaceuticals Holdings AB

• GlaxoSmithKline Plc

• Pfizer Inc

• Sanofi SA

• Johnson & Johnson

*Similar analysis will be provided for each company listed above.